Submission Preparation ChecklistAs part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
- The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
- The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
- Where available, URLs for the references have been provided.
- The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
- The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.
Instructions for Authors
The Experimental and Biomedical Research publishes articles in English. Since the journal does not offer translation services, if the language of the manuscripts is not enough, the editors may refuse the manuscript or ask the author to seek language editorial services to bring the manuscript to minimum standards for the review process. If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.
If you would like to submit a Review, please contact Editor-in Chief at firstname.lastname@example.org.
The articles must be submitted by the corresponding author via the Online Submissions System. If authors encounter technical problems with online submission, they may contact with support team at email@example.com.
The corresponding author’s must do: complete submission of manuscript files; storage of the article and all related documents and giving original data when necessary; contributions of the authors and explanations of conflict of interest disclosures; approval for submission; and the final proof control.
The corresponding author should present his/her ORCiD ID in the registration process.
Author Declaration, Funding and Financial Conflicts of Interest
Authors should provide a cover letter declares: that the article submitted has not been published elsewhere and is not under review; that the submission has been approved by all co-authors and, if necessary, by the responsible authorities and the institute. The publisher will not be responsible in cases of any claims for compensation.
All authors should disclose commercial ties or consulting, stock or share interests or patent license arrangements that can be viewed as a conflict of interest in relation to the manuscript presented (Author Declaration Form & Conflict Of Interest Statement).
Obtaining permission form the copyright owner/ owners is obligatory for figures, tables or texts that previously published elsewhere if the authors want to add them to their manuscripts. Without this evidence, any material used in the article will be deemed to be an original product of the authors.
Peer Review Policy
Experimental Biomedical Research is committed to maintaining the high quality of the peer-review process. Once the suitability of the article submitted has been affirmed by the editor, it will then be processed to double blind peer-review by referees who are experts in the field. The authors may suggest three potential peer reviewers who can make an objective assessment and who are expert in the field of the work. Reviewers suggested by authors will be only take into account when other appropriate reviewer candidates are not available. If revision needed, authors are expected to return manuscript to the Journal within 30 days after revision request. Final proofs are needed to be returned in 3 days.
Units of measurement
The International System of Units (SI) is the modern form of the metric system, and is the most widely used system of measurement. Therefore, units of measurement should be presented using the International System of Units in Experimental Biomedical Research.
Abbreviations are defined at the first mention and are then used continuously. The authors should always be used standard abbreviations and generic names of the drugs. Additionally, the abbreviations presented in the Tables and Figures must be compatible with SI. If registered trademarks are used, the name and country of the manufacturer must be given in parentheses following the generic name on the first use.
Preparation of Manuscript
The title page should include: manuscript title, the name(s), the affiliation(s) and address (es) of the author(s).
The corresponding author information should include the e-mail address, the 16-digit ORCID ID, telephone number(s) and full mailing address.
Disclosure of conflict of interest, funding organizations and acknowledgments of people, grants, funds, etc. should be placed in the last section on the title page.
Abstracts must not exceed 250 words. The abstract should describe with subheadings; Aim, Method, Results, and Conclusions. Abstracts should not be contain any unexplained abbreviations or references.
4 to 6 keywords are sufficient which can be recommended by the "Index Medicus Subject Headings": MeSH (http://www.nlm.nih.gov/mesh/meshhome.html).
The main text should describe with subheadings; Introduction, Materials and Methods, Results, Discussion and Conclusions. Manuscripts should be submitted in Microsoft Office Word formats and arranged as 12-point Times New Roman for text. References to literature, figures and tables should be placed in the order of their citation in the text. The Author(s) should not use italics, bold or underlined words in the texts. Please use only generic names of drugs.
Conflicts of Interest
Authors must declare all relevant interests that could be perceived as conflicting. Authors should explain why each interest may represent a conflict. If no conflicts exist, the authors should state this. Submitting authors are responsible for coauthors declaring their interests.
Number references in the order they are mentioned in the text; do not alphabetize. Reference citations in the text should be identified by numbers in square brackets. In listing references, follow NLM Style Guide, abbreviating names of journals according to Index Medicus. Indicate each author’s family name followed by a space and initials closed up without periods. Author names should be separated with a comma, never using the conjunction “and” between entries. All authors must be listed for papers with 1 to 6 authors. For papers with more than 6 authors, only the first 6 authors must be listed, followed by et al.
For online journals or articles published online ahead of print, provide the DOI number, if possible, rather than the URL. URLs used in references will not be made hyperlinks.
List the first six authors;
Bothra J, Shah H, Tiwar C. Classic Wilms’ tumor with raised alpha-fetoprotein levels: A case report and literature review. Ped Urol Case Rep. 2017; 4(1):238-42.
More than six authors followed by et al.
Nondel B, Lazarus J, Howlett J, McCulloch M, Nourse P, Moonsamy G et al. Donated staghorn kidney stone in an HIV positive pediatric kidney transplant recipient. Ped Urol Case Rep. 2017; 4(4):350-5.
Chapter in a book
Luck H. Catalase. In: Bergmeyer HU, edİtor. Methods of Enzymatic Analysis. New York: Academic Press; 1971. p. 885-93.
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. [cited 2016 Dec 27]. Available from:http://www.rsc.org/dose/title of subordinate document.
The authors are responsible for the accurate and in full presentation in accordance with the journal's style of references.
Preparation of Figures and Tables
The figures and tables should be uploaded electronically by a separate file and should be stated consecutively in the text. Each table should have an explanatory heading, and if numerical measurements are made, the units should be added to the column header. Figures should be presented in vector image formats (Illustrator, EPS, WMF, FreeHand, CorelDraw, PowerPoint, Excel etc.) or in bitmap formats (Photoshop, TIFF, GIF, JPEG, etc.). Bitmap images should be at least 300 dpi resolution.
Authors can submit one file of supplementary material such as audio files, video clips, or datasets. A section titled “Supplementary Material” should be included before the references list with a concise description for each supplementary material file. Authors are responsible for providing the final supplementary materials files that will be published along with the article.
English Language Editing
Ethical Responsibilities of Authors
Experimental Biomedical Research journal will follow the Committee on Publication Ethics (COPE) guidelines on how to deal with potential acts of misconduct. For this reason, authors should protected the journal trust, the professionalism of the scientific authorship, and must refrain from misrepresenting the consequences of research that could destroy all scientific effort.
Articles sent to Experimental Biomedical Research journal are checked for possible plagiarism by using an appropriate software (iThenticate). However, corresponding and co-authors are responsible for any fraud, intentional or unintentional malpractice.
Research involving human participants and/or animals
All work should be done with the permission of local human subjects or animal care committees (institutional and national) and clinical trials should be registered to legislation. The official numbers from these committees must be found in the text.
All submitted manuscripts which report in vivo experiments or clinical trials must have a written statement in the Methods section of the articles what protocols were followed, eg, ‘‘Institutional guidelines regarding animal experimentation were followed.’’
1) Statement of human rights
The studies involving human participants should state that the research has been endorsed by the institutional and / or national research ethics committee and that it is conducted in accordance with the ethical standards set out in the Helsinki Declaration of 1964, and that subsequent changes are also met (1).
2) Statement on the welfare of animals
If you have done experimental research on animals, authors should indicate whether the international, national and / or institutional guidelines for the care and use of the animals are followed, and whether the work has been approved by an institutional research ethics committee.
If manuscripts report the results of an experimental research of human subjects, all authors must fulfill the International Committee of Medical Journal Editors (ICMJE) requirements on confidentiality and informed consent from patients and study participants. Therefore;
1- Informed consent is obtained from all participants before they are included in the work.
2- Distinguishing details of the participants examined (name, date of birth, identification numbers and other information) should not be published in print, photographs and genetic profiles.
3-Where someone is deceased, please make sure that you have written permission from the family or estate.
4-If the identification features are changed to protect anonymity as in genetic profiling, the authors should assure that the changes do not distort scientific meaning.
Authors may use this Patient Consent Form, which sent to the journal if requested.
The journal reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines.
There are no submission fees or page charges for Experimental Biomedical Research journal.
Articles published in Experimental Biomedical Research are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Upon acceptance of an article, authors will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. A letter will be sent to the corresponding author confirming receipt of the manuscript. A form facilitating transfer of copyright will be provided. (Copyright Transfer Agreement Form).
If the article contains a figure or table produced from a book or other journal article, the authors must obtain permission from the copyright owner before submitting the manuscript and they will be entirely liable for legal and / or financial consequences if such authorization documents are not obtained.
If you wish to use PDF, HTML, XML files or any artwork published in this journal for any commercial purpose, please contact the publisher at firstname.lastname@example.org.
Accepted articles are sent as portable document format (PDF) files, along with proof by e-mail to the relevant author for approval. Corrections to PDF evidence should be limited to posting errors only, and no significant additions / deletions should be made. Authors are responsible for all statements made in their work, including changes made by the copy editor and authorized by the author concerned. Authors are strongly advised to thoroughly examine the PDF evidence and return the proofs within 3 days.
Experimental Biomedical Research
Completed authorship forms may be mailed to this address.
1-World Medical Association.Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/ 30publications/10policies/b3/index.html. Accessed October 14, 2010.
Peer Review Process
Experimental Biomedical Research is an online-only, international, peer-reviewed, open access journal.
The undersigned author(s) certify (ies) that the submitted manuscript is original, is not under consideration by any other journal, and has not been previously published. All submissions to the journal are initially reviewed by the Editor. At this stage manuscripts may be rejected without peer review if it is felt that they are not high enough priority or not relevant to the journal.
Experimental Biomedical Research (Editor) reviews new submissions according to its guidelines. When they meet all criteria, Editor-in-Chief sends two referees (double blind) and all manuscripts are read by reviewers, and revisions to the manuscript may be required. If the decision conflicts between two reviewers, it will be send to third peer reviewer. The typical review will take in 2-4 weeks. When the manuscript is received from peer reviewer there will be one of the following outcome and the Editor-in-Chief may decide to: 1) accepted manuscript without revisions, 2) invite authors to resubmit the manuscript after minor or major changes while the final decision is kept pending, 3) or reject the manuscript. When the manuscript is returned for revision prior to acceptance, the revised manuscript must be submitted within two week after the author's receipt of the referee's reports.
Each manuscript will be accepted (sometimes on a conditional basis pending suggested changes) or declined based on the reviewers’ comments, and Editor-in-Chief’s decisions. It is a condition of submission of a paper that the authors permit editing of the paper for readability. In the case of a controversial ground breaking manuscript that could have far-reaching impact on the field, further reviews may be sought. The decision ultimately rests with the Editor-in-Chief. Further correspondence and proofs will be sent to the author(s) before publication unless otherwise indicated.
Manuscript submission, evaluation and decision process
- New manuscript submission
- Manuscript plagiarism and technical check
- Manuscript ID assigned
- First editorial review (for peer review/ accepted/rejected)
- Double-blind peer review (2-4 weeks)
- Second editorial review (accepted/minor revision/major revision/rejected)
- Decision sent to the authors
- Revision received from the authors (two week)
- Third editorial review (re-peer review/accepted/rejected)
- Final decision sent to the authors.
Experimental Biomedical Research journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.